ArticleEuropean journal of nuclear medicine and molecular imaging2020
Performance of the PET vascular activity score (PETVAS) for qualitative and quantitative assessment of inflammatory activity in Takayasu's arteritis patients.
Article in European journal of nuclear medicine and molecular imaging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07628075 (Long-Axial Field of View), which is not on this map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Long-Axial Field of View (LAFOV) [18F]FDG PET/CT Imaging in Large Vessel Vasculitis (LVV): Protocol Optimisation Study.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it.
- 2025 Chinese guideline for the imaging diagnosis and evaluation of Takayasu arteritis.Advances in rheumatology (London, England) · 2025Guideline
- Superior correlation with clinical activity and unique detection patterns: a prospective study of FAPI versus FDG-PET in polymyalgia rheumatica and giant cell arteritis.European journal of nuclear medicine and molecular imaging · 2026Article
- Utility of contrast-enhanced ultrasound for assessing disease activity in takayasu arteritis with carotid artery involvement: a scoping review.Frontiers in immunology · 2026Article
- Advances in the pathophysiology, diagnosis and treatment of Takayasu arteritis.Nature reviews. Rheumatology · 2025Review
- The Role of Imaging in Monitoring Large Vessel Vasculitis: A Comprehensive Review.Biomolecules · 2025Review
- Association of PET vascular activity score with Takayasu's arteritis angiographic progression.European journal of nuclear medicine and molecular imaging · 2025Observational
- Innovations in Imaging:Current cardiology reports · 2024Review
- Chinese guideline for the diagnosis and treatment of Takayasu's arteritis (2023).Rheumatology and immunology research · 2024Review
- Advanced molecular imaging in large-vessel vasculitis: Adopting FDG-PET into a clinical workflow.Best practice & research. Clinical rheumatology · 2023Review
- Updates on the diagnosis and monitoring of giant cell arteritis.Frontiers in medicine · 2023Review
- A methodological framework for AI-assisted diagnosis of active aortitis using radiomic analysis of FDG PET-CT images: Initial analysis.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2022Article
- The role of PET/CT in disease activity assessment in patients with large vessel vasculitis.Rheumatology (Oxford, England) · 2022Article
- Outcome Measures and Biomarkers for Disease Assessment in Takayasu Arteritis.Diagnostics (Basel, Switzerland) · 2022Review
- Molecular imaging as a tool for evaluation of COVID-19 sequelae - A review of literature.World journal of radiology · 2022Review
- Intraoperative fluorescence molecular imaging accelerates the coming of precision surgery in China.European journal of nuclear medicine and molecular imaging · 2022Review
- Assessment of Takayasu arteritis in routine practice with PETVAS, an 18F-FDG PET quantitative scoring tool.Turkish journal of medical sciences · 2022Article
- Comparing Semiquantitative and Qualitative Methods of VascularJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Observational
- Advances in Takayasu arteritis: An Asia Pacific perspective.Frontiers in medicine · 2022Review
- Establishment and Optimization of Radiomics Algorithms for Prediction of KRAS Gene Mutation by Integration of NSCLC Gene Mutation Mutual Exclusion Information.Frontiers in pharmacology · 2022Article
- Application progress of multiple imaging modalities in Takayasu arteritis.The international journal of cardiovascular imaging · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
purposeTo assess the performance of PET vascular activity score (PETVAS) in comparison with SUVmax, inflammatory biomarkers and ITAS-2010 score in a cohort of TAK patients.
methodsSixty-four PET/CT scans acquired from 54 TAK patients were analyzed. The inflammatory activity was qualitatively determined by physician's global assessment and quantitatively determined by ITAS-2010 score. SUVmax and PETVAS were acquired by consensus review. Levels of the inflammatory biomarkers C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and pentraxin-3 (PTX-3) were measured. Performance of the qualitative diagnoses and the quantitative correlation were, respectively, compared by receiver operating characteristic (ROC) curve and Spearman correlation coefficient.
resultsThe biomarkers (CRP, ESR, PTX-3), PET uptake values (SUVmax, PETVAS), and ITAS-2010 scores were all significantly higher in active patients than in non-active ones. The area under the ROC curve and Youden Index of PETVAS and PTX-3 were higher than those of SUVmax, CRP, ESR, and ITAS-2010. PETVAS and PTX-3 resulted in a higher Spearman correlation coefficient with ITAS-2010 than other criteria, either among all patients or within the active group. Alteration trends of PETVAS and PTX-3 during follow-up showed a tighter correlation with clinical progression/remission assessment than other criteria.
conclusionsIn TAK evaluation, PETVAS is superior for qualitative and quantitative assessment, compared with the regional SUVmax. Compared to CRP and ESR, inflammatory biomarker PTX-3 shows better qualitative performance and a higher correlation with PETVAS and ITAS-2010. These findings indicate that the use of PETVAS and PTX-3, instead of SUVmax and CRP/ESR, has potential advantages in the clinical evaluation of TAK.
Indexed as
Identifiers
32567005What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.